CHRNA7: Neuronal acetylcholine receptor subunit alpha-7
Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction.
- Drugs that act on it: 17
- Approved: 0
- In phases 1 to 3: 17
- Sponsors: 12
Who is on it, and how far along
Every drug ChEMBL records acting on CHRNA7, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 13
- Other 4
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- CoMentis212%
- Targacept212%
- AbbVie16%
- Asmacure Ltée16%
- AstraZeneca Pharmaceuticals16%
- Bionomics16%
- FORUM Pharmaceuticals Inc16%
- Johnson & Johnson16%
- Memory Pharmaceuticals16%
- Mitsubishi Tanabe Pharma16%
| Encenicline | Phase 3 | FORUM Pharmaceuticals Inc | Small molecule | Partial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist | 0 |
| ABT-126 | Phase 2 | AbbVie | Small molecule | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
| AQW051 | Phase 2 | Novartis Pharmaceuticals | Small molecule | Partial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist | 0 |
| ASM-024 | Phase 2 | Asmacure Ltée | Other | ModulatorNeuronal acetylcholine receptor protein alpha-7 subunit modulator | 0 |
| AZD0328 | Phase 2 | AstraZeneca Pharmaceuticals | Small molecule | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
| BNC-210 | Phase 2 | Bionomics | Other | Negative allosteric modulatorNeuronal acetylcholine receptor protein alpha-7 subunit negative allosteric modulator | 0 |
| Bradanicline | Phase 2 | Targacept | Small molecule | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
| Facinicline | Phase 2 | Memory Pharmaceuticals | Small molecule | Partial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist | 0 |
| GTS-21 | Phase 2 | CoMentis | Small molecule | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
| JNJ-39393406 | Phase 2 | Johnson & Johnson | Small molecule | Positive allosteric modulatorNeuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator | 0 |
| ND0801 | Phase 2 | Mitsubishi Tanabe Pharma | Other | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
| SSR180711 | Phase 2 | Sanofi | Small molecule | Partial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist | 0 |
| TC-6987 | Phase 2 | Targacept | Small molecule | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
| ABT-107 | Phase 1 | — | Small molecule | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
| APN1125 | Phase 1 | CoMentis | Other | Partial agonistNeuronal acetylcholine receptor protein alpha-7 subunit partial agonist | 0 |
| AVL-3288 | Phase 1 | — | Small molecule | Positive allosteric modulatorNeuronal acetylcholine receptor protein alpha-7 subunit positive allosteric modulator | 0 |
| PHA-543613 | Phase 1 | — | Small molecule | AgonistNeuronal acetylcholine receptor protein alpha-7 subunit agonist | 0 |
- Alzheimer disease0.44
- Neurodegenerative disease0.35
- Increased total eosinophil count0.32
- Schizophrenia0.32
- Abnormality of limbs0.31
- Social phobia0.28
- Male reproductive organ cancer0.27
- Preeclampsia0.27
- Kidney disorder0.25
- Parkinson disease0.24
- Lysosomal storage disease0.21
- Asthma0.13
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2492, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P36544, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets